Full Text View
Tabular View
No Study Results Posted
Related Studies
Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide
This study is currently recruiting participants.
Verified by Capital District Health Authority, Canada, August 2009
First Received: November 15, 2006   Last Updated: August 5, 2009   History of Changes
Sponsor: Capital District Health Authority, Canada
Information provided by: Capital District Health Authority, Canada
ClinicalTrials.gov Identifier: NCT00400088
  Purpose

This study is being done to look at how well people respond to two very different drug treatments for depression. Clinically, people with depression can respond differently to drug treatments for reasons which are not always clear. Some of our own recent research suggests that people with depression who have a family history of bipolar disorder or completed suicide, may react differently to standard antidepressant medications than those without such a family history. Our data shows that family history of completed suicide, as well as the known predictor of family history of bipolar disorder, may help identify a pre-bipolar high risk group i.e. they currently have depression but at some future date will declare a bipolar illness (manic-depression) by virtue of development of a manic episode also. Our research suggests that treatment- emergent symptoms in response to a trial of antidepressant, such as agitation may be strong predictors of future bipolarity and inherently dangerous particularly as they are not ascribed to the antidepressant treatment. Finally, it is possible that this subgroup of those with depressive illness may respond better and more safely to lithium, a mood stabiliser used in known bipolar depression.

The objective of this proposal is to investigate response to acute lithium treatment in subjects who meet the diagnostic criteria for major depression, but who are potentially at risk for bipolar disorder, by virtue of family history of bipolarity or completed suicide.


Condition Intervention Phase
Major Depressive Disorder
Drug: paroxetine
Drug: lithium
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study

Resource links provided by NLM:


Further study details as provided by Capital District Health Authority, Canada:

Primary Outcome Measures:
  • Response will be defined as 50% reduction in MADRS score. [ Time Frame: weekly ] [ Designated as safety issue: Yes ]
  • Remission will be defined as MADRS ≤ 12. [ Time Frame: weekly ] [ Designated as safety issue: Yes ]
  • The MADRS will be done at week 0,1,2,3,4,5,6. [ Time Frame: weekly ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The Hamilton Depression Rating Scale (HAM -D)-17 item scale, at weeks 0 and 6. [ Time Frame: weeks 0 and 6 ] [ Designated as safety issue: Yes ]
  • Hamilton Anxiety Rating Scale (HAM-A),at weeks 0 and 6. [ Time Frame: weeks 0 and 6 ] [ Designated as safety issue: No ]
  • The Young Mania Rating Scale (YMRS), at weeks 0,1,2,3,4,5,6. [ Time Frame: weekly ] [ Designated as safety issue: Yes ]
  • The Bipolar Depression Rating Scale (BDRS) (42),at weeks 0,1,2,3,4,5,6. [ Time Frame: weekly ] [ Designated as safety issue: Yes ]
  • Checklist of DSM IV symptoms of mania/ hypomania, with additional questions assessing the presence of mood lability, abnormally high energy, abnormally high libido, and rage. Done at weeks 0,1,2,3,4,5,6. [ Time Frame: weekly ] [ Designated as safety issue: Yes ]
  • The Beck Suicide Scale (BSS), at weeks 0, 1, 2,3,4,5, 6. [ Time Frame: weekly ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 20
Study Start Date: June 2007
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
lithium group: Experimental
Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
Drug: lithium
start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
paroxetine group: Active Comparator
Start dose at 20 mg po od. If no clinical improvement(<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.
Drug: paroxetine
Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Not currently participating in a drug or medical device clinical trial
  • Male or female over the age of 18
  • DSM - IV Diagnosis of major depression
  • Positive family history of bipolar disorder or completed suicide

Exclusion Criteria:

  • Not able to give informed consent
  • Pregnant or breast-feeding
  • Current additional psychiatric diagnoses including Panic Disorder, Post -Traumatic Stress Disorder (PTSD) or Psychosis
  • History of mania or hypomania
  • Active substance abuse or dependence in the last 6 months
  • Current depressive episode less than 4 weeks or greater than 12 months in duration
  • Current or prior adequate trial of lithium or paroxetine
  • Current use of other medications such as antidepressants for the treatment of depression
  • Clinically significant medical illness, in particular kidney problems
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00400088

Contacts
Contact: Claire M O'Donovan, MB FRCPC (902) 473 - 2585 claire.odonovan@cdha.nshealth.ca
Contact: Julie S Garnham, BN (902) 473 - 7144 jgarnham@dal.ca

Locations
Canada, Nova Scotia
Capital District Health Authority - Dept. of Psychiatry Recruiting
Halifax, Nova Scotia, Canada, B3H 2E2
Contact: Julie S Garnham, BN     (902) 473 7144     jgarnham@dal.ca    
Contact: Claire Slaney, RN     (902) 473 - 5884     claire.slaney@cdha.nshealth.ca    
Principal Investigator: Claire M O'Donovan, MB FRCPC            
Sponsors and Collaborators
Capital District Health Authority, Canada
Investigators
Principal Investigator: Claire O'Donovan M O'Donovan, MB FRCPC Capital District Health Authority and Dalhousie University
  More Information

Publications:
Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003 Jan;73(1-2):123-31.
Perugi G, Micheli C, Akiskal HS, Madaro D, Socci C, Quilici C, Musetti L. Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients. Compr Psychiatry. 2000 Jan-Feb;41(1):13-8.
Roy-Byrne P, Post RM, Uhde TW, Porcu T, Davis D. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl. 1985;317:1-34.
Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P, Beaulieu S, Daigneault A, Milev R, Young LT, Ravindran A, Schaffer A, Connolly M, Gorman CP; Canadian Network for Mood and Anxiety Treatments. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7 Suppl 3:5-69. Review.
Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004 Jan;161(1):163-5.
Blacker D, Lavori PW, Faraone SV, Tsuang MT. Unipolar relatives in bipolar pedigrees: a search for indicators of underlying bipolarity. Am J Med Genet. 1993 Dec 15;48(4):192-9.
Bowden CL. A different depression: clinical distinctions between bipolar and unipolar depression. J Affect Disord. 2005 Feb;84(2-3):117-25.
Strober M, Carlson G. Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Arch Gen Psychiatry. 1982 May;39(5):549-55.
Hirschfeld RM, Cass AR, Holt DC, Carlson CA. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract. 2005 Jul-Aug;18(4):233-9.
Koukopoulos A, Faedda G, Proietti R, D'Amico S, de Pisa E, Simonetto C. [Mixed depressive syndrome] Encephale. 1992 Jan;18 Spec No 1:19-21. French.
Berk M, Dodd S. Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression? Med Hypotheses. 2005;65(1):39-43.

Responsible Party: Department of Psychiatry Dalhousie University ( Dr Claire O'Donovan )
Study ID Numbers: CDHA012, CDHA-RS/2006-076
Study First Received: November 15, 2006
Last Updated: August 5, 2009
ClinicalTrials.gov Identifier: NCT00400088     History of Changes
Health Authority: Canada: Health Canada

Keywords provided by Capital District Health Authority, Canada:
Major Depressive Disorder
Depression
Bipolar Disorder
Manic Depressive Illness
Randomized Trial
Antidepressant Treatment
Lithium Treatment

Additional relevant MeSH terms:
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Depressive Disorder, Major
Paroxetine
Affective Disorders, Psychotic
Pathologic Processes
Mental Disorders
Therapeutic Uses
Antidepressive Agents, Second-Generation
Lithium
Antidepressive Agents
Disease
Depression
Tranquilizing Agents
Bipolar Disorder
Lithium Carbonate
Central Nervous System Depressants
Enzyme Inhibitors
Depressive Disorder
Antimanic Agents
Antipsychotic Agents
Serotonin Uptake Inhibitors
Pharmacologic Actions
Behavioral Symptoms
Serotonin Agents
Mood Disorders
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 22, 2009